SG11201903801YA - Pyridone compound as c-met inhibitor - Google Patents
Pyridone compound as c-met inhibitorInfo
- Publication number
- SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA
- Authority
- SG
- Singapore
- Prior art keywords
- met inhibitor
- pyridone compound
- met
- pyridone
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610954377 | 2016-10-27 | ||
| PCT/CN2017/107964 WO2018077227A1 (fr) | 2016-10-27 | 2017-10-27 | Composé de pyridone en tant qu'inhibiteur de c-met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903801YA true SG11201903801YA (en) | 2019-05-30 |
Family
ID=62024383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903801YA SG11201903801YA (en) | 2016-10-27 | 2017-10-27 | Pyridone compound as c-met inhibitor |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10501443B2 (fr) |
| EP (1) | EP3533787B1 (fr) |
| JP (1) | JP6719679B2 (fr) |
| KR (1) | KR102070748B1 (fr) |
| CN (1) | CN109311812B (fr) |
| AU (1) | AU2017348810B2 (fr) |
| BR (1) | BR112019008415B1 (fr) |
| CA (1) | CA3041164C (fr) |
| CO (1) | CO2019005165A2 (fr) |
| DK (1) | DK3533787T3 (fr) |
| EA (1) | EA038108B1 (fr) |
| ES (1) | ES2835301T3 (fr) |
| HR (1) | HRP20201985T1 (fr) |
| HU (1) | HUE051734T2 (fr) |
| IL (1) | IL266126B (fr) |
| LT (1) | LT3533787T (fr) |
| MX (1) | MX2019004626A (fr) |
| MY (1) | MY189557A (fr) |
| PE (1) | PE20190912A1 (fr) |
| PH (1) | PH12019500875A1 (fr) |
| PL (1) | PL3533787T3 (fr) |
| PT (1) | PT3533787T (fr) |
| RS (1) | RS61126B1 (fr) |
| SG (1) | SG11201903801YA (fr) |
| SI (1) | SI3533787T1 (fr) |
| UA (1) | UA122737C2 (fr) |
| WO (1) | WO2018077227A1 (fr) |
| ZA (1) | ZA201903074B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI768205B (zh) | 2018-04-26 | 2022-06-21 | 大陸商福建廣生堂藥業股份有限公司 | 一種c-MET抑制劑的晶型及其鹽型和製備方法 |
| CN113365997B (zh) * | 2019-02-01 | 2022-06-07 | 南京明德新药研发有限公司 | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 |
| WO2022063869A2 (fr) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Composés pour le traitement d'infections virales |
| EP4346829A1 (fr) | 2021-06-04 | 2024-04-10 | Merck Patent GmbH | Composés pour le traitement du glioblastome |
| WO2024206858A1 (fr) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions pour induire une hydrolyse de ras gtp et leurs utilisations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001275857A1 (en) | 2000-06-29 | 2002-01-14 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
| EP1741703A4 (fr) | 2004-03-05 | 2009-11-25 | Banyu Pharma Co Ltd | Derive pyridone |
| CA2676173A1 (fr) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Ketones heterocyclyles contenant de l'azote et leur utilisation comme inhibiteurs de c-met |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| EP2768826A1 (fr) | 2011-10-17 | 2014-08-27 | Bayer Intellectual Property GmbH | Oxadiazolyl-pyridinones et -pyridazinones substituées servant d'inhibiteurs de hif |
| EP2827872A1 (fr) * | 2012-03-19 | 2015-01-28 | Merck Patent GmbH | Combinaison d'un dérivé de 6-oxo-1,6-dihydro-pyridazine ayant une activité anticancéreuse avec d'autres composés anti-tumoraux |
| WO2014056566A1 (fr) * | 2012-10-11 | 2014-04-17 | Merck Patent Gmbh | Association d'un dérivé de 6-oxo-1,6-dihydro-pyridazine présentant une activité anticancéreuse à un inhibiteur de mek |
| KR20170090498A (ko) * | 2014-12-11 | 2017-08-07 | 메르크 파텐트 게엠베하 | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합 |
-
2017
- 2017-10-27 HU HUE17864813A patent/HUE051734T2/hu unknown
- 2017-10-27 PE PE2019000855A patent/PE20190912A1/es unknown
- 2017-10-27 MX MX2019004626A patent/MX2019004626A/es active IP Right Grant
- 2017-10-27 DK DK17864813.5T patent/DK3533787T3/da active
- 2017-10-27 LT LTEP17864813.5T patent/LT3533787T/lt unknown
- 2017-10-27 AU AU2017348810A patent/AU2017348810B2/en active Active
- 2017-10-27 EP EP17864813.5A patent/EP3533787B1/fr active Active
- 2017-10-27 BR BR112019008415-0A patent/BR112019008415B1/pt active IP Right Grant
- 2017-10-27 KR KR1020197014236A patent/KR102070748B1/ko active IP Right Grant
- 2017-10-27 CN CN201780036464.XA patent/CN109311812B/zh active Active
- 2017-10-27 PL PL17864813T patent/PL3533787T3/pl unknown
- 2017-10-27 EA EA201990952A patent/EA038108B1/ru unknown
- 2017-10-27 PT PT178648135T patent/PT3533787T/pt unknown
- 2017-10-27 SG SG11201903801YA patent/SG11201903801YA/en unknown
- 2017-10-27 ES ES17864813T patent/ES2835301T3/es active Active
- 2017-10-27 UA UAA201904417A patent/UA122737C2/uk unknown
- 2017-10-27 CA CA3041164A patent/CA3041164C/fr active Active
- 2017-10-27 MY MYPI2019002142A patent/MY189557A/en unknown
- 2017-10-27 RS RS20201448A patent/RS61126B1/sr unknown
- 2017-10-27 SI SI201730558T patent/SI3533787T1/sl unknown
- 2017-10-27 WO PCT/CN2017/107964 patent/WO2018077227A1/fr unknown
- 2017-10-27 US US16/343,387 patent/US10501443B2/en active Active
- 2017-10-27 JP JP2019540379A patent/JP6719679B2/ja active Active
-
2019
- 2019-04-18 IL IL266126A patent/IL266126B/en active IP Right Grant
- 2019-04-22 PH PH12019500875A patent/PH12019500875A1/en unknown
- 2019-05-16 ZA ZA2019/03074A patent/ZA201903074B/en unknown
- 2019-05-21 CO CONC2019/0005165A patent/CO2019005165A2/es unknown
-
2020
- 2020-12-10 HR HRP20201985TT patent/HRP20201985T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| SG11201903801YA (en) | Pyridone compound as c-met inhibitor | |
| NZ729005A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| PH12016500467B1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MX2014012454A (es) | Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria. | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| MY194116A (en) | Pharmaceutical compounds | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
| JO3318B1 (ar) | مثبطات bace | |
| PH12016502246A1 (en) | Carboxamide derivatives | |
| MX2018014813A (es) | Composiciones antibacterianas. | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX2016013265A (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor |